Prolonged Continuous Electrocardiographic Monitoring Prior to Transcatheter Aortic Valve Replacement: The PARE Study.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
10 08 2020
Historique:
received: 22 01 2020
revised: 16 03 2020
accepted: 24 03 2020
pubmed: 20 7 2020
medline: 1 4 2021
entrez: 20 7 2020
Statut: ppublish

Résumé

This study sought to determine, using continuous electrocardiographic monitoring (CEM) pre-transcatheter aortic valve replacement (TAVR), the incidence and type of unknown pre-existing arrhythmic events (AEs) in TAVR candidates, and to evaluate the occurrence and impact of therapeutic changes secondary to the detection of AEs pre-TAVR. Scarce data exist on the arrhythmic burden of TAVR candidates (pre-procedure). This was a prospective study including 106 patients with severe aortic stenosis and no prior permanent pacemaker screened for TAVR. A prolonged (1 week) CEM was implanted within the 3 months pre-TAVR. Following heart team evaluation, 90 patients underwent elective TAVR. New AEs were detected by CEM in 51 (48.1%) patients, leading to a treatment change in 14 of 51 (27.5%) patients. Atrial fibrillation or tachycardia was detected in 8 of 79 (10.1%) patients without known atrial fibrillation or tachycardia, and nonsustained ventricular arrhythmias were detected in 31 (29.2%) patients. Significant bradyarrhythmias were observed in 22 (20.8%) patients, leading to treatment change and permanent pacemaker in 8 of 22 (36.4%) and 4 of 22 (18.2%) patients, respectively. The detection of bradyarrhythmias increased up to 30% and 47% among those patients with pre-existing first-degree atrioventricular block and right bundle branch block, respectively. Chronic renal failure, higher valve calcification, and left ventricular dysfunction determined (or tended to determine) an increased risk of AEs pre-TAVR (p = 0.028, 0.052, and 0.069, respectively). New onset AEs post-TAVR occurred in 22.1% of patients, and CEM pre-TAVR allowed early arrhythmia diagnosis in one-third of them. Prolonged CEM in TAVR candidates allowed identification of previously unknown AEs in nearly one-half of the patients, leading to prompt therapeutic measures (pre-TAVR) in about one-fourth of them. Pre-existing conduction disturbances (particularly right bundle branch block) and chronic renal failure were associated with a higher burden of AEs.

Sections du résumé

OBJECTIVES
This study sought to determine, using continuous electrocardiographic monitoring (CEM) pre-transcatheter aortic valve replacement (TAVR), the incidence and type of unknown pre-existing arrhythmic events (AEs) in TAVR candidates, and to evaluate the occurrence and impact of therapeutic changes secondary to the detection of AEs pre-TAVR.
BACKGROUND
Scarce data exist on the arrhythmic burden of TAVR candidates (pre-procedure).
METHODS
This was a prospective study including 106 patients with severe aortic stenosis and no prior permanent pacemaker screened for TAVR. A prolonged (1 week) CEM was implanted within the 3 months pre-TAVR. Following heart team evaluation, 90 patients underwent elective TAVR.
RESULTS
New AEs were detected by CEM in 51 (48.1%) patients, leading to a treatment change in 14 of 51 (27.5%) patients. Atrial fibrillation or tachycardia was detected in 8 of 79 (10.1%) patients without known atrial fibrillation or tachycardia, and nonsustained ventricular arrhythmias were detected in 31 (29.2%) patients. Significant bradyarrhythmias were observed in 22 (20.8%) patients, leading to treatment change and permanent pacemaker in 8 of 22 (36.4%) and 4 of 22 (18.2%) patients, respectively. The detection of bradyarrhythmias increased up to 30% and 47% among those patients with pre-existing first-degree atrioventricular block and right bundle branch block, respectively. Chronic renal failure, higher valve calcification, and left ventricular dysfunction determined (or tended to determine) an increased risk of AEs pre-TAVR (p = 0.028, 0.052, and 0.069, respectively). New onset AEs post-TAVR occurred in 22.1% of patients, and CEM pre-TAVR allowed early arrhythmia diagnosis in one-third of them.
CONCLUSIONS
Prolonged CEM in TAVR candidates allowed identification of previously unknown AEs in nearly one-half of the patients, leading to prompt therapeutic measures (pre-TAVR) in about one-fourth of them. Pre-existing conduction disturbances (particularly right bundle branch block) and chronic renal failure were associated with a higher burden of AEs.

Identifiants

pubmed: 32682674
pii: S1936-8798(20)30816-5
doi: 10.1016/j.jcin.2020.03.031
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1763-1773

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Lluis Asmarats (L)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Isabelle Nault (I)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Alfredo Nunes Ferreira-Neto (AN)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Guillem Muntané-Carol (G)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

David Del Val (D)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Lucia Junquera (L)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Jean-Michel Paradis (JM)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Robert Delarochellière (R)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Siamak Mohammadi (S)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Dimitri Kalavrouziotis (D)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Eric Dumont (E)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Emilie Pelletier-Beaumont (E)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

François Philippon (F)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada.

Josep Rodés-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH